Bee pollen, because of its high content of nutrients, is a very valuable medicinal and nutritional product. However, since its composition is not completely studied, the consumption of this product may cause adverse effects, including allergic reactions. Therefore, this study aimed to discover and characterize the bioactive proteins of bee pollen collected in Poland, focusing mainly on the allergens. For this purpose, the purified and concentrated pollen aqueous solutions were analyzed using the nanoLC-MALDI-TOF/TOF MS analytical platform. As a result of the experiments, 197 unique proteins derived from green plants (Viridiplantae) and 10 unique proteins derived from bees (Apis spp.) were identified. Among them, potential plant allergens were discovered. Moreover, proteins belonging to the group of hypothetical proteins, whose expression had not been confirmed experimentally before, were detected. Because of the content of bioactive compounds—both beneficial and harmful—there is a critical need to develop guidelines for standardizing bee pollen, especially intended for consumption or therapeutic purposes. This is of particular importance because awareness of the allergen content of bee pollen and other bee products can prevent health- or life-threatening incidents following the ingestion of these increasingly popular “superfoods”.

FDA-approved kinase inhibitors represent a rapidly growing class of targeted therapies with proven clinical success in oncology. However, their occupancy-driven mode of action is often associated with resistance, off-target effects, and incomplete inhibition. Proteolysis-Targeting Chimaeras (PROTACs) offer a compelling alternative by promoting complete degradation of oncogenic kinases, thereby enhancing selectivity and resistance reduction. In this review, we provide a comprehensive overview of the rational design, development, and synthetic approaches for PROTACs incorporating FDA-approved kinase inhibitors. We discuss key aspects influencing degrader efficiency, including kinase selectivity, linker design, E3 ligase recruitment, and synthetic strategies. Additionally, we highlight recent advances, emerging trends, and future directions, such as expanding the repertoire of degradable kinases, optimising linker chemistry, and broadening diversity of E3 ligases. A better understanding of these factors will facilitate the continued evolution of PROTAC technology into effective next-generation therapies for kinase-driven diseases.

The paper compares the experimental FT-IR, UV-vis, and ¹H NMR spectra of isoconazole and bifonazole with the density functional theory (DFT) calculations using different functionals. The results were compared with previously reported data related to their analogue, posaconazole. The analysis of calculated IR spectra with use of CAM-B3LYP (isoconazole) or B3LYP (bifonazole) functionals shows good accordance with the experimental IR spectrum. The best compatibility between the experimental and theoretical UV spectra was observed with the use of B3LYP or wB97XD functionals for isoconazole or bifonazole, respectively. The reason for the difference in the UV-vis spectra of isoconazole and bifonazole was discussed based on linear response time-dependent DFT and natural bond orbital methods. The calculated ¹H NMR spectrum shows that the DFT formalism, particularly the B3LYP functional, give an accurate description of the isoconazole and bifonazole chemical shifts.

Traditional synthetic methods, often limited by inefficiency, are increasingly being replaced by sustainable alternatives. This study presents a green approach combining microwave irradiation with in situ FTIR spectroscopy for real-time monitoring and optimising nitrogen-heterocycle synthesis, focusing on quinoxalines. Although both microwave-assisted synthesis and time-resolved FTIR are established techniques, their combined application remains underexplored, limiting their synergistic potential. The methodology was applied to synthesising 2,3-diphenylquinoxaline, a compound of interest in medicinal chemistry. Optimisation of the condensation between benzil and 1,2-phenylenediamine was achieved by exploiting the accelerated kinetics of microwave irradiation and continuous monitoring via in situ FTIR. Three catalytic systems were evaluated—hydrochloric acid (Brønsted acid), Montmorillonite K10 (heterogeneous catalyst), and molecular iodine (halogen/Lewis acid)—alongside a range of solvents, including ethanol, methanol, water, acetonitrile, ethyl acetate, dimethyl sulfoxide, and dichloromethane. Iodine proved to be the most efficient catalyst, while acetonitrile and ethyl acetate provided the most effective solvent systems. This integrated monitoring strategy reduces reliance on trial-and-error optimisation and establishes a streamlined, scalable, and efficient protocol. The dual-technique approach highlights a versatile pathway for advancing green synthetic methodologies with applications across the chemical and pharmaceutical industries.

Glioblastoma (GBM) is the most aggressive malignancy of the central nervous system. Among novel therapeutic strategies, the development of two‑drug hybrid molecules -single entities composed of two pharmacophores - has emerged as a promising approach. Principal component analysis of structural and physicochemical descriptors of cannabinoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and CBD–NSAID hybrids revealed distinct physicochemical profiles for each group, suggesting that the hybrids may possess new and potentially advantageous functionalities. Thus, this study aimed to synthesize and biologically characterize five novel hybrid molecules composed of cannabidiol (CBD) and selected NSAIDs: ibuprofen (IBU), ketoprofen (KET), naproxen (NAP), indomethacin (INDO), and sulindac (SUL). Cytotoxicity analyses (MTT assay) in GBM T98G and U-138 MG cells, as well as non‑cancerous MRC‑5 cells, demonstrated potent anti‑GBM activity of the hybrids - particularly CBD–IBU - together with a more favorable toxicity profile toward normal cells. Using the Luminex MAGPIX® multiplex immunoassay system, we observed that the hybrids modulate key GBM‑related signaling molecules, including NF‑κB, STAT3, STAT5, AKT, p70, p70S6K, JNK, ERK1/2, p38, and CREB. Additionally, in silico docking studies revealed strong predicted binding of the hybrids - especially CBD–SUL - to the Keap1 Kelch domain. In conclusion, our study provides preliminary evidence supporting the anti‑GBM potential of these novel CBD–NSAID hybrid molecules. However, further mechanistic studies and in‑depth in vivo evaluation are needed to fully validate their therapeutic applicability.